Oncobiologics Inc.
7 Clarke Drive
Cranbury
New Jersey
08512
United States
Tel: 609-619-3990
Fax: 609-619-3980
Website: http://oncobiologics.com/
Email: bd@oncobiologics.com
37 articles about Oncobiologics Inc.
-
What’s Going on With the Biosimilar Market?
12/10/2018
Although a moderate presence in Europe, with about 25 biosimilars approved and on the market, they haven’t gained traction in the U.S. Even though at least 11 have been approved in the U.S., only about three are available, largely because of business tactics branded drug companies are using to sl... -
Oncobiologics Reports First Quarter Fiscal Year 2018 Results
2/14/2018
On an adjusted basis, Oncobiologics had a net loss attributable to common stockholders for the three months ended December 31, 2017 of $5.0 million.
-
Oncobiologics Receives Positive Nasdaq Listing Determination
2/14/2018
The Company’s current market capitalization is approximately $30 million.
-
Oncobiologics Announces Term Extension of Series A Warrants - Feb. 12, 2018
2/12/2018
The Series A warrants were issued as part of the units in Oncobiologics’ May 2016 initial public offering and are exercisable for shares of its common stock at an exercise price of $6.60 per share.
-
Oncobiologics Announces Closing of Strategic Partnership Deal With GMS Tenshi Holdings
10/31/2017
The deal builds a strategic partnership to accelerate the commercialization of Oncobiologics’ biosimilar candidates.
-
Oncobiologics Announces Strategic Partnership With GMS Tenshi Holdings Pte. Limited
9/11/2017
-
Oncobiologics Announces Strategic Partnership With GMS Tenshi Holdings Pte. Limited
9/8/2017
-
Oncobiologics Closes On Final Portion Of $15 Million Senior Secured Note And Warrant Offering
6/1/2017
-
Oncobiologics Secures Additional Funding
4/17/2017
-
Oncobiologics Announces Term Extension Of Series A Warrants
2/7/2017
-
Oncobiologics Release: Biopharma Issues Remaining Senior Secured Notes And Warrants–Raising An Aggregate $10.0 Million
1/11/2017
-
Oncobiologics Issues $8.35 Million Of Senior Secured Notes And Warrants To Acquire 1.9 Million Shares As Part Of Aggregate $10.0 Million Note And 2.3 Million Warrant Offering
12/27/2016
-
Oncobiologics Announces Presentation Of Final Data From Phase I Clinical Study Of ONS-3010 (HUMIRA Biosimilar)
11/14/2016
-
Oncobiologics To Present At Biocentury’s Newsmakers In The Biotech Industry Conference
9/1/2016
-
Oncobiologics Announces Pricing Of Its Initial Public Offering Of Units
5/13/2016
-
Premier, Inc. And Oncobiologics Align To Advance Adoption Of Biosimilar Drugs
3/3/2016
-
Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Members
12/14/2015
-
Oncobiologics Announces ONS-1045 (Avastin/bevacizumab biosimilar) Meets Primary And Secondary Endpoints In Phase 1 Clinical Trial
10/5/2015
-
Oncobiologics Secures Financing From Sabby Management, LLC, To Advance BioSymphony Platform And Monoclonal Antibody Biosimilars Pipeline
9/29/2015
-
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer
9/16/2015